<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672087</url>
  </required_header>
  <id_info>
    <org_study_id>2010P000229</org_study_id>
    <secondary_id>NIH DK065990</secondary_id>
    <nct_id>NCT00672087</nct_id>
  </id_info>
  <brief_title>Diagnostic Challenges in IC (and Male CPPS)</brief_title>
  <official_title>Diagnostic Challenges in IC (and Male CPPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etiology and pathogenesis of interstitial cystitis (IC) and its related condition in men,
      chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has remained elusive. This has
      hampered development of mechanistic treatment strategies for these common, chronic and
      distressing medical conditions. We believe that IC and perhaps CP/CPPS are a spectrum of
      complex but inter-related genetic and acquired diseases resulting from the interaction of
      several genes regulating immune/inflammatory and neurogenic parameters and environmental
      factors/circumstances or exposure, culminating in the combination of pain, frequency, urgency
      and sexual specific symptoms. New research has delineated the dynamic and powerful
      association of the immune and neurogenic system in pain activation. An immune-modulated
      neurogenic model of IC illuminating the action of immune derived substances and pain related
      substances might be important in discovering the determinants of pain, voiding dysfunction
      and gender specific sexual problems. This inter-related dynamic model of IC disease
      pathogenesis could be explored for potential avenues leading to novel diagnostic and
      treatment strategies. We plan to identify and evaluate the sensitivity and specificity of
      several novel nerve and inflammation related markers in the diagnosis and follow up of IC
      (and CP/CPPS). By correlating the levels of urine immune and pain related substances to
      disease mechanisms, severity and progression, we may be able to create a human disease
      specific model for diagnosis and treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Prostatitis With Chronic Pelvic Pain Syndrome</condition>
  <condition>Chronic Bacterial Prostatitis</condition>
  <condition>Asymptomatic Inflammatory Prostatitis</condition>
  <condition>Painful Bladder Syndrome</condition>
  <condition>Cystitis, Interstitial</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Chronic prostatitis/chronic pelvic pain syndrome patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Painful bladder syndrome/interstitial cystitis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>Asymptomatic controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genomic and proteomic biomarker discovery</intervention_name>
    <description>Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      saliva, whole blood, serum, white cells, urine, prostatic fluid, prostate/bladder tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary university medical centers and primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has signed and dated the appropriate Informed Consent document.

          -  Participant must have had symptoms of discomfort or pain in the pelvic region for at
             least a three (3) month period within the last six (6) months.

        Exclusion Criteria:

          -  Major structural/anatomical urinary tract abnormalities

          -  Underlying inborn conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan D Dimitrakoff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard Medical School, Boston, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dimitrakov J, Kroenke K, Steers WD, Berde C, Zurakowski D, Freeman MR, Jackson JL. Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. Arch Intern Med. 2007 Oct 8;167(18):1922-9. Review. Erratum in: Arch Intern Med. 2007 Dec 10-22;167(22):2452.</citation>
    <PMID>17923590</PMID>
  </reference>
  <reference>
    <citation>Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR. Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach. Urology. 2006 May;67(5):881-8. Review.</citation>
    <PMID>16698346</PMID>
  </reference>
  <reference>
    <citation>Allsop SA, Erstad DJ, Brook K, Bhai SF, Cohen JM, Dimitrakoff JD. The DABBEC phenotyping system: towards a mechanistic understanding of CP/CPPS. Nat Rev Urol. 2011 Feb;8(2):107-13. doi: 10.1038/nrurol.2010.227. Epub 2011 Jan 18. Review.</citation>
    <PMID>21243018</PMID>
  </reference>
  <reference>
    <citation>Strauss AC, Dimitrakov JD. New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nat Rev Urol. 2010 Mar;7(3):127-35. doi: 10.1038/nrurol.2010.4. Epub 2010 Feb 9. Review.</citation>
    <PMID>20142810</PMID>
  </reference>
  <results_reference>
    <citation>Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington CA, Nickel JC. Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2008 Feb;71(2):261-6. doi: 10.1016/j.urology.2007.09.025.</citation>
    <PMID>18308097</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <name_title>Jordan Dimitrakoff, MD, PhD, Director of Urogynecology and Chronic Pelvic Pain Lab</name_title>
    <organization>Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA</organization>
  </responsible_party>
  <keyword>Chronic Prostatitis with Chronic Pelvic Pain Syndrome</keyword>
  <keyword>Chronic Bacterial Prostatitis</keyword>
  <keyword>Asymptomatic Inflammatory Prostatitis</keyword>
  <keyword>Painful Bladder Syndrome</keyword>
  <keyword>Cystitis, Interstitial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Prostatitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

